WASHINGTON — The FDA has approved updated COVID-19 vaccines for the 2026–27 respiratory-virus season, clearing new formulations from Moderna, Pfizer-BioNTech and Novavax-Sanofi ahead of the fall vaccination campaign.

The updated shots are designed to target the XFG variant, the strain selected for the new season.

The approved vaccines include Moderna’s mNEXSPIKE and Spikevax, Pfizer-BioNTech’s Comirnaty, and the protein-based Novavax-Sanofi vaccine.

The decision gives pharmacies, physicians and health systems the green light to begin preparing for another fall vaccination push as respiratory illnesses typically rise when colder weather returns.

The update matters because COVID-19 vaccines are reformulated periodically as the virus changes, much like seasonal flu shots are adjusted to better match circulating strains.

For consumers, the practical question will be which product is available locally and whether insurance covers it without out-of-pocket cost.

The protein-based Novavax option may also appeal to people who prefer a vaccine that does not use mRNA technology.

The FDA’s approval does not mean every person will necessarily be advised to receive the updated shot. Recommendations on who should get vaccinated and when typically depend on federal public-health guidance, age, health status and individual risk.

Older adults, people with weakened immune systems and those with underlying medical conditions generally face the greatest risk of severe COVID-19 illness.

The updated vaccines are expected to begin reaching pharmacies and healthcare providers ahead of the fall respiratory season.

For families planning flu and COVID vaccinations together, the approval provides clarity that the next generation of COVID shots is ready for distribution.

JBizNews Desk | Washington

© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.